DNA vaccines encoding li-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency

被引:76
作者
Hung, Chien-Fu
Tsai, Ya-Chea
He, Liangmei
Wu, T-C
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Mol Microbiol & Immunol, Baltimore, MD USA
[4] Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21205 USA
关键词
D O I
10.1038/sj.mt.6300121
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
It is now clear that CD4(+) T cells play a crucial role in the generation of CD8(+) T effector and memory T-cell immune responses. In this study, we enhanced the CD4(+) T-cell immune responses in mice by constructing a DNA vaccine encoding an invariant (Ii) chain in which the class II-associated Ii peptide (CLIP) region is replaced with a CD4(+) T-helper epitope, PADRE (Ii-PADRE) (invariant Pan HLA-DR reactive epitope). C57BL/6 mice vaccinated with DNA encoding Ii-PADRE showed significantly greater PADRE-specific CD4(+) T-cell immune responses than mice vaccinated with DNA encoding the Ii chain alone (Ii DNA). More important, administration of DNA encoding human papillomavirus (HPV) E6 or E7 antigen with DNA encoding Ii-PADRE led to significantly stronger E6- or E7-specific CD8(+) T-cell immune responses and more potent protective and therapeutic anti-tumor effects against an E6/E7-expressing tumor model in mice than administration of E6 or E7 DNA with Ii DNA. Overall, our data indicate that administration of DNA vaccines with Ii-PADRE DNA represents an effective approach to enhancing the generation of CD4(+) T cells and eliciting stronger antigen-specific CD8(+) T-cell immune responses. Therefore, this strategy may be expected to have significant potential for clinical translation.
引用
收藏
页码:1211 / 1219
页数:9
相关论文
共 33 条
[1]   DEVELOPMENT OF HIGH POTENCY UNIVERSAL DR-RESTRICTED HELPER EPITOPES BY MODIFICATION OF HIGH-AFFINITY DR-BLOCKING PEPTIDES [J].
ALEXANDER, J ;
SIDNEY, J ;
SOUTHWOOD, S ;
RUPPERT, J ;
OSEROFF, C ;
MAEWAL, A ;
SNOKE, K ;
SERRA, HM ;
KUBO, RT ;
SETTE, A ;
GREY, HM .
IMMUNITY, 1994, 1 (09) :751-761
[2]   Induction of a CD8(+) cytotoxic T lymphocyte response by cross-priming requires cognate CD4(+) T cell help [J].
Bennett, SRM ;
Carbone, FR ;
Karamalis, F ;
Miller, JFAP ;
Heath, WR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :65-70
[3]   Helping the CD8+ T-cell response [J].
Bevan, MJ .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (08) :595-602
[4]   Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma [J].
Bloom, MB ;
PerryLalley, D ;
Robbins, PF ;
Li, Y ;
ElGamil, M ;
Rosenberg, SA ;
Yang, JC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (03) :453-459
[5]   ROLE FOR INTRACELLULAR PROTEASES IN THE PROCESSING AND TRANSPORT OF CLASS-II HLA ANTIGENS [J].
BLUM, JS ;
CRESSWELL, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (11) :3975-3979
[6]   Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes [J].
Bousso, P ;
Robey, E .
NATURE IMMUNOLOGY, 2003, 4 (06) :579-585
[7]   Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4 T cell-dendritic cell interaction [J].
Castellino, F ;
Huang, AY ;
Altan-Bonnet, G ;
Stoll, S ;
Scheinecker, C ;
Germain, RN .
NATURE, 2006, 440 (7086) :890-895
[8]   Cooperation between CD4+ and CD8+ T cells:: When, where, and how [J].
Castellino, Flora ;
Germain, Ronald N. .
ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 :519-540
[9]  
Chen CH, 2000, CANCER RES, V60, P1035
[10]  
Cheng WF, 2001, J CLIN INVEST, V108, P669, DOI 10.1172/JCI12346